Related Experiment Video
Updated: Aug 4, 2026
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
Published on: July 28, 2012
Quantitative studies of the kinetics of 5-aminolaevulinic acid-induced fluorescence in bladder transitional cell
S N Datta1, C S Loh, A J MacRobert
1Department of Urology, University Hospital of Wales, Cardiff, UK.
Abstract:
Photodynamic therapy is a potential treatment for superficial bladder cancer that utilizes photosensitizer drugs, which are activated by light to cause tissue destruction. However, first-generation photosensitizers cause prolonged phototoxicity, have poor tumour specificity and can accumulate within detrusor muscle, resulting in permanent loss of bladder capacity following treatment. A newer drug, called 5-aminolaevulinic acid (ALA), generates a sensitizer called protoporphyrin IX (PpIX) in situ and has been shown, qualitatively, to be more tumour specific. The fluorescence kinetics of ALA-induced PpIX was investigated in patient biopsies of bladder tumour, normal urothelium and detrusor muscle, both in vitro after incubation of specimens in ALA-rich culture medium for various times and in vivo after instillation of intravesical ALA before endoscopic resection. The fluorescence in tumour tissue was twice that of normal urothelium in vitro and up to tenfold in vivo. There was little ALA-induced fluorescence in detrusor muscle, both in vitro and in vivo. Most importantly, no patients experienced phototoxicity or other adverse events following intravesical instillation of ALA.
Insights
Newer 5-aminolaevulinic acid (ALA) photodynamic therapy shows improved tumor specificity for bladder cancer. ALA generates protoporphyrin IX (PpIX) with minimal detrusor muscle accumulation and no phototoxicity in patients.
Area of Science:
- Oncology
- Photochemistry
- Urology
Background:
- Photodynamic therapy (PDT) offers a potential treatment for superficial bladder cancer.
- First-generation photosensitizers exhibit limitations including prolonged phototoxicity and poor tumor specificity, potentially affecting bladder capacity.
Purpose of the Study:
- To investigate the fluorescence kinetics of 5-aminolaevulinic acid (ALA)-induced protoporphyrin IX (PpIX) in bladder tumor and normal tissues.
- To evaluate the tumor specificity and safety of ALA-induced PpIX for bladder cancer treatment.
Main Methods:
- In vitro analysis of ALA-induced PpIX fluorescence in patient bladder tumor, normal urothelium, and detrusor muscle biopsies.
- In vivo assessment of ALA-induced PpIX fluorescence after intravesical ALA instillation prior to endoscopic resection.
- Quantification of fluorescence in tumor, normal urothelium, and detrusor muscle.
Main Results:
- Tumor tissue exhibited twofold higher PpIX fluorescence than normal urothelium in vitro.
- In vivo, tumor fluorescence was up to tenfold higher compared to normal urothelium.
- Minimal ALA-induced fluorescence was observed in detrusor muscle both in vitro and in vivo.
- No patients reported phototoxicity or adverse events post-treatment.
Conclusions:
- 5-aminolaevulinic acid (ALA) demonstrates superior tumor specificity for bladder cancer compared to first-generation photosensitizers.
- ALA-induced PpIX photodynamic therapy is a promising treatment with a favorable safety profile, minimizing side effects and preserving bladder function.
